Am Fam Physician. 2024;110(5):537-538
Author disclosure: No relevant financial relationships.
Brexpiprazole (Rexulti) is an atypical antipsychotic medication labeled for the treatment of agitation associated with Alzheimer disease. It acts as a partial agonist on the 5-HT1A serotonin and D2 dopamine receptors and as an antagonist on the 5-HT2A serotonin receptor.1 Brexpiprazole is also labeled for use in treating schizophrenia and as an adjunctive therapy for major depressive disorder.1
| Drug | Dosage | Dose form | Cost of full course* |
|---|---|---|---|
| Brexpiprazole (Rexulti) | 0.5 mg/day taken orally to start (days 1–7), titrate to 1 mg/day on days 8–14, and to target dosage of 2 mg/day on day 15; may increase dosage to 3 mg/day on day 28 based on clinical response | Tablets: 0.5 mg, 1 mg, 2 mg, 3 mg | $1,500 |
Already a member/subscriber?
Log In
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available
Purchase Access:
Learn More
